The Effect of Bevacizumab versus Ranibizumab in the Treatment of Corneal Neovascularization: A Preliminary Study.
10.3341/kjo.2013.27.4.235
- Author:
Jin Hyoung KIM
1
;
Hae Won SEO
;
Hyun Cheol HAN
;
Jong Hyun LEE
;
Suk Kyue CHOI
;
Doh LEE
Author Information
1. Department of Ophthalmology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea. eyedr0823@hotmail.com
- Publication Type:Original Article ; Comparative Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Corneal neovascularization;
Ranibizumab
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Angiogenesis Inhibitors/*therapeutic use;
Antibodies, Monoclonal, Humanized/*therapeutic use;
Corneal Neovascularization/*drug therapy;
Female;
Humans;
Male;
Middle Aged;
Pilot Projects;
Prospective Studies;
Treatment Outcome;
Young Adult
- From:Korean Journal of Ophthalmology
2013;27(4):235-242
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To compare the short term effects of bevacizumab and ranibizumab injections on the regression of corneal neovascularization (NV). METHODS: Sixteen eyes of 16 patients with corneal NV were randomly assigned for an injection with 2.5 mg of bevacizumab (group 1, n = 8) or 1 mg of ranibizumab (group 2, n = 8) through subconjunctival and intrastromal routes. The patients were prospectively followed-up for one month after the injections. Corneal NV areas, as shown on corneal slit-lamp photographs stored in JPEG format, were calculated using Image J software before the injection, one week after the injection, and one month after the injection. The corneal NV areas were compared before and after the injections. RESULTS: Seven women and nine men, with an average age of 51 years, presented with corneal NV secondary to herpetic keratitis (7 cases), graft rejection (6), chemical burn (1), pemphigoid (1), and recurrent ulcer (1). In group I, the preoperative corneal NV area (8.75 +/- 4.33%) was significantly decreased to 5.62 +/- 3.86% one week after the injection and to 6.35 +/- 3.02% one month after the injection (p = 0.012, 0.012, respectively). The corneal NV area in group 2 also exhibited a significant change, from 7.37 +/- 4.33% to 6.72 +/- 4.16% one week after the injection (p = 0.012). However, no significant change was observed one month after the injection. The mean decrease in corneal NV area one month after injection in group 1 (28.4 +/- 9.01%) was significantly higher than in group 2 (4.51 +/- 11.64%, p = 0.001). CONCLUSIONS: Bevacizumab injection resulted in a more effective and stable regression of corneal NV compared to the ranibizumab injection. The potency and dose of these two drugs for the regression of corneal NV require further investigation.
